☆ 4.6 Review

Systemic therapy with or without locoregional therapy for advanced hepatocellular carcinoma: A systematic review and network meta-analysis

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials

Alessandro Di Federico et al.

Summary: This article discusses the main evidence regarding the use of Y-90-TARE in HCC, the recent progress of immunotherapy in this tumor, and the preclinical rationale of combining VEGF blockade with the other two treatment strategies. HCC has an extremely heterogeneous tumor immune microenvironment. Combining an immune-checkpoint inhibitor with VEGF blockade and Y-90-TARE might overcome primary resistances observed when each of these treatments is administered alone.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

Add to Collection

Editorial Material Oncology

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Masatoshi Kudo

LIVER CANCER (2022)

Add to Collection

Review Gastroenterology & Hepatology

Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?

Alessandro Rizzo et al.

Summary: This article discusses the available evidence regarding predictive biomarkers of response to immunotherapy in hepatocellular carcinoma (HCC) patients, highlighting the need for further research on biochemical predictors of response to immune checkpoint inhibitors (ICIs) in HCC.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Oncology

Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers

Vera Himmelsbach et al.

Summary: The combination therapy of atezolizumab and bevacizumab has shown high efficacy and manageable toxicity in the treatment of hepatocellular carcinoma, with better prognosis in patients with viral hepatitis.

CANCERS (2022)

Add to Collection

Article Oncology

Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)

Zhenwei Peng et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley et al.

Summary: This study evaluated the combination of cabozantinib and atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. The combination treatment group showed better progression-free survival compared to the sorafenib group, but overall survival did not reach statistical significance. Common adverse events in the combination group included liver enzyme elevation, hypertension, and skin reactions. The study suggests that cabozantinib plus atezolizumab may be a treatment option, but further research is needed.

LANCET ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

R. S. Finn et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

S. Qin et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

S. Qin et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Review Oncology

Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis

Giuseppe Viscardi et al.

Summary: This study analyzed the incidence of early death (ED) in randomized clinical trials (RCTs) using immune checkpoint inhibitors. The results showed that the risk of ED was higher when immune checkpoint inhibitors were used alone compared to non-immune checkpoint inhibitor therapies, while the risk was lower when they were used in combination with other therapies. Patients with gastric cancer and urothelial carcinoma were at a higher risk of ED. PD-L1 expression and the class of immune checkpoint inhibitor drugs were not associated with ED.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma

Giuseppe Cabibbo et al.

LANCET ONCOLOGY (2022)

Add to Collection

Review Oncology

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: In this article, Llovet and colleagues review recent advances in hepatocellular carcinoma therapy and discuss the clinical workflows for selecting and monitoring patients. The article covers the molecular pathogenesis of HCC, molecular classes and determinants of heterogeneity, and effective systemic therapies including immunotherapy. The authors propose a flowchart of sequential therapies, explore mechanisms of resistance, and address the need for predictive biomarkers.

NATURE CANCER (2022)

Add to Collection

Review Gastroenterology & Hepatology

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Josep M. Llovet et al.

HEPATOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Donafenib: First Approval

Susan J. Keam et al.

Summary: Donafenib is an oral multikinase inhibitor developed by Suzhou Zelgen Biopharmaceuticals Co., Ltd. for the treatment of various cancers, including hepatocellular carcinoma. It recently received its first approval in China for unresectable hepatocellular carcinoma, marking a significant milestone in its development.

DRUGS (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Gastroenterology & Hepatology

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Locoregional therapies, including local ablation and transarterial chemoembolization, play a crucial role in the management of hepatocellular carcinoma. Recent studies have shown potential benefits of combining these local therapies with systemic treatments, such as molecular therapies, to enhance therapeutic effects.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Review Immunology

Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis

Ziniu Ding et al.

Summary: Viral etiology may not serve as a selection criteria for patients receiving ICIs in HCC, and viral status has limited impact on TIME remodeling during HCC tumorigenesis.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Oncology

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

Alessandro Rizzo et al.

Summary: Immune checkpoint inhibitors, particularly the combination of PD-L1 inhibitor and antiangiogenic agent, have emerged as novel systemic treatment options for advanced HCC. Despite this, reliable predictors of response to immunotherapy in HCC patients remain unanswered questions.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Dermatology

Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis

J. I. Silverberg et al.

Summary: Network meta-analyses compared the efficacy and safety of different systemic therapies in patients with moderate-to-severe atopic dermatitis, revealing that abrocitinib, dupilumab, and upadacitinib were the most effective systemic treatment options.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The study investigated the impact of NASH on immunotherapy response in HCC patients and found that NASH-HCC may be less responsive to immunotherapy. Aberrant T cell activation caused by NASH-related tissue damage led to impaired immune surveillance in HCC patients.

NATURE (2021)

Add to Collection

Review Gastroenterology & Hepatology

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)

Philipp K. Haber et al.

Summary: A review of 49 high-quality phase III randomized controlled trials in hepatocellular carcinoma conducted between 2002 and 2020 found that 9 had positive results, suggesting that immunotherapies may be more effective in viral etiologies.

GASTROENTEROLOGY (2021)

Add to Collection

Article Oncology

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Shukui Qin et al.

Summary: This study demonstrated that donafenib is more effective than sorafenib in treating advanced hepatocellular carcinoma, showing promise in improving patients' survival outcomes, and exhibiting favorable safety profile.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study

Changhoon Yoo et al.

Summary: In patients with advanced hepatocellular carcinoma who experienced disease progression on atezolizumab-bevacizumab, second-line treatment with multikinase inhibitors, predominantly sorafenib and lenvatinib, demonstrated comparable efficacy and manageable toxicities.

LIVER CANCER (2021)

Add to Collection

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The text discusses the impact of NASH on the development of HCC and the effect of immunotherapy, revealing the accumulation of exhausted and unconventionally activated CD8(+)PD1(+) T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, anti-PD1 treatment led to an increase in HCC, with CD8(+) T cells contributing to this increase.

NATURE (2021)

Add to Collection

Review Gastroenterology & Hepatology

Review article: new therapeutic interventions for advanced hepatocellular carcinoma

Saroja Bangaru et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Review Oncology

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis

Jianchun Duan et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Editorial Material Oncology

Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure

Khashayar Farsad et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Health Care Sciences & Services

GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks

Romina Brignardello-Petersen et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2019)

Add to Collection

Review Gastroenterology & Hepatology

Combined locoregional-immunotherapy for liver cancer

Tim F. Greten et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma

Jean-Louis Jouve et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Article Oncology

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial

MinKe He et al.

JAMA ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma

Kai Wen Huang et al.

JOURNAL OF CLINICAL MEDICINE (2019)

Add to Collection

Article Oncology

Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West

V. H. F. Lee et al.

CLINICAL ONCOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma

Jens Ricke et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Article Oncology

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Phase 3 CALGB 80802 Randomized Clinical Trial

Ghassan K. Abou-Alfa et al.

JAMA ONCOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial

Joong-Won Park et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach et al.

HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero et al.

HEPATOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

Add to Collection

Article Oncology

Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis

Susan Feyerabend et al.

EUROPEAN JOURNAL OF CANCER (2018)

Add to Collection

Article Oncology

TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials

Dae-Won Lee et al.

BRITISH JOURNAL OF CANCER (2016)

Add to Collection

Article Medicine, General & Internal

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

Brian Hutton et al.

ANNALS OF INTERNAL MEDICINE (2015)

Add to Collection

Article Oncology

SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

Andrew X. Zhu et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

Calin Cainap et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Review Oncology

Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design

Josep M. Llovet et al.

CLINICAL CANCER RESEARCH (2014)

Add to Collection

Article Oncology

Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis

Hajime Aino et al.

MOLECULAR AND CLINICAL ONCOLOGY (2014)

Add to Collection

Article Public, Environmental & Occupational Health

Evaluation of inconsistency in networks of interventions

Areti Angeliki Veroniki et al.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2013)

Add to Collection

Article Oncology

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Philip J. Johnson et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Oncology

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

Ann-Lii Cheng et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Mathematical & Computational Biology

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

Georgia Salanti

RESEARCH SYNTHESIS METHODS (2012)

Add to Collection

Article Health Care Sciences & Services

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

Georgia Salanti et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)

Add to Collection

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

Add to Collection

Article Oncology

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann-Lii Cheng et al.

LANCET ONCOLOGY (2009)

Add to Collection

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.